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The Kaposi’s Sarcoma-associated Herpesvirus (KSHV)-encoded G-protein coupled receptor (vGPCR) is an oncoprotein that is 
implicated in KSHV-associated malignancies. We previously revealed vGPCR incorporates sulfate groups within its extracel-
lular N-terminal tyrosine residues (Y26 and Y28) and that this tyrosine sulfation is crucial for its tumorigenicity in nude mice. 
hGRO- binds vGPCR in a sulfotyrosine-dependent manner and promotes its tumorigenicity through autocrine signaling. In-
terestingly, an unsulfated vGPCR mutant (yydd-vGPCR) attenuated the tumor growth triggered by hGRO-. In this study, the 
extracellular N-terminus of vGPCR (wt-vGN) and an unsulfated vGPCR mutant (yydd-vGN) were individually secreted, ex-
pressed and purified. A radioactive labeling assay demonstrated that wt-vGN but not yydd-vGN incorporated [35S]-sulfate. In 
nude mice, NIH3T3 cells expressing yydd-vGN but not wt-vGN could significantly inhibit the tumor growth triggered by 
hGRO-. All our data support the conclusion that the unsulfated extracellular N-terminus of vGPCR reduces the tumorigenicity of 
hGRO-. 
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Kaposi’s sarcoma (KS) is an angioproliferative neoplasm 
consisting of characteristic spindle cells and infiltrating 
leukocytes, and is a leading cause of morbidity and mortal-
ity among the AIDS population. The Kaposi’s sarcoma-       
associated herpesvirus (KSHV, also known as human her-
pesvirus 8, or HHV-8) is the etiologic agent for Kaposi’s 
sarcoma (KS), as well as primary effusion lymphoma and 
multicentric Castleman’s disease [1–4]. KSHV is a DNA 
virus and belongs to the gamma-2 herpesvirus family, and is 
closely related to herpesvirus saimiri (HVS) and rhesus 
monkey rhadinovirus (RRV). The genome of KSHV is ap-
proximately 165–170 kb and contains more than 80 open 
reading frames. As one of several recently identified human 
tumor viruses, KSHV has been extensively studied to elu-
cidate the mechanism of its tumorigenicity. Indeed, the 
KSHV genome encodes an array of proteins that are impli-
cated in modulating host inflammatory responses, angio-
genesis and tumor formation, most notably the G protein-      
coupled receptor (vGPCR or ORF74) [5–7].  
vGPCR is the homolog of human interleukin-8 receptor 
(IL-8R or CXCR2). However, unlike its cellular counterpart, 
it is constitutively activated even in the absence of ligand 
association [8]. vGPCR triggers downstream signaling 
components including the phospholipase C pathway, and 
PI3 kinase/AKT axis, and has broad signaling effects in 
vitro, activating NF-B, NFAT and AP-1 [9–14]. Emerging 
evidence supports that this KHSV lytic gene is an oncogene: 
vGPCR-transformed cells led to tumorigenesis in nude mice 
and vGPCR transgenic mice developed the human KS-like 
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disease [15,16]. 
vGPCR constitutively activates downstream signaling 
even without ligand association. However, chemokines such 
as GRO- and IP-10 bind vGPCR and modulate its signal-
ing. Accumulating evidence suggests that the N-terminus of 
vGPCR is important for its chemokine association and tu-
morigenicity [17–20]. Understanding the molecular details 
of vGPCR association with chemokines will advance our 
knowledge of the regulatory mechanisms that govern 
vGPCR signaling and tumorigenesis and will inform the 
efforts to develop therapy targeting vGPCR in the treatment 
of KS.  
Our previous study showed that vGPCR contains sulfated 
tyrosine residues at the N-terminus (Y26 and Y28), which 
are necessary for GRO- but not IP-10 binding. Sulfotyro-
sines at positions 26 and 28 are not critical for signaling 
downstream of vGPCR. However, they are crucial for the 
tumorigenicity of vGPCR in nude mice and human GRO- 
(hGRO-) promotes vGPCR tumorigenesis in a sulfotyro-
sine-dependent manner. Unsulfated yydd-vGPCR (in which 
the tyrosines at positions 26 and 28 have been mutated to 
aspartic acid) was not tumorigenic in nude mice [21]. Inter-
estingly, the tumor forming ability of NIH3T3 cells express-
ing hGRO- was consistently reduced by yydd-vGPCR ex-
pression [21], which implied yydd-vGPCR (more precisely 
its unsulfated extracellular N-terminus) decreased the tu-
morigenicity of hGRO-.  
In this study, chimeras comprising the extracellular 
N-terminus of vGPCR or yydd-vGPCR and mouse Fc 
(fragment, crystallizable) region were constructed (wt-vGN-      
mFc and yydd-vGN-mFc, respectively). These fusion pro-
teins were individually secreted, expressed and purified by 
affinity chromatography from whole cell lysates or the me-
dia supernatant. Radioactive labeling demonstrated that 
wt-vGN-mFc but not yydd-vGN-mFc recruited [35S]-sulfate. 
In nude mice experiments, the tumor forming ability of 
NIH3T3 cells expressing hGRO- was consistently reduced 
by the expression of yydd-vGN-mFc but not by wt-vGN-    
mFc expression. Also, the tumorigenicity of vGPCR in vivo 
was reduced by yydd-vGN-mFc. All these data support the 
conclusion that the unsulfated extracellular N-terminus of 
vGPCR reduces the tumorigenicity of hGRO- in vivo.   
1  Materials and methods  
1.1  Cells and plasmids 
HEK293T (293T) cells and NIH3T3 cells were obtained 
from the American Type Culture Collection (ATCC, Ma-
nassas/USA). NIH3T3 cells stably expressing vGPCR or 
hGRO-α were kept in the lab. All cells were grown in 
DMEM supplemented with 10% fetal bovine serum, 100 
units mL1 penicillin and 100 g mL1 streptomycin.  
DNA fragments encoding the extracellular N-terminal 
region (amino acid 1–49 of vGPCR (wt-vGN) or yydd-      
vGPCR (yydd-vGN) were PCR-amplified and cloned into 
pSecTag2A (Invitrogen) between the Asc I and Xho I sites. 
Mouse Fc fragment (mFc) was PCR-amplified using a 
plasmid encoding LSF-mouse Fc hinge as the template (a 
kind gift from Dr. Feng PingHui, USC) and cloned into the 
above constructs between the Xho I and Apa I sites (pSec-
Tag2A-wt-vGN-mFc and pSecTag2A-yydd-vGN-mFc ac-
cordingly).  
For lentiviral vector constructs, wt-vGN-mFc or yydd- 
vGN-mFc were excised and cloned into pCDH-CMV-     
EF-Puro (System Bioscience) between the Nhe I and Pme I 
sites (CDH-wt-vGN-mFc and CDH-yydd-vGN-mFc accord-
ingly). Lentivirus containing wt-vGN-mFc or yydd-vGN-      
mFc was made as described previously and NIH3T3 cells 
stably expressing wt-vGN-mFc or yydd-vGN-mFc were 
established as previously [22]. 
1.2  Expression and purification of wt-vGN and yydd- 
vGN  
293T cells were transfected with either pSecTag-wt-vGN-     
mFc or pSecTag-yydd-vGN-mFc (10 dishes (100 mm×20 
mm) of cells for per construct). Cells were harvested at 48 h 
post-transfection and lysed in Lysis Buffer-Tween (50 
mmol L1 Tris-Hcl, pH 7.4, 150 mmol L1 NaCl, 1% NP-40, 
5 mmol L1 EDTA, 0.05% Tween-20) containing protease 
inhibitor cocktail (Roche, Shanghai, China). Both the cell 
lysates and the media supernatant were incubated with 5% 
Ni-NTA Magnetic Agarose Bead suspension (QIAGEN, 
Shanghai, China) on ice for 1 h. The beads were washed and 
eluted according to the manufacturer’s protocol. A total of 
100 μL eluate of each sample was obtained, of which 10 μL 
was used for Coomassie brilliant blue (CBB) staining.  
For the secreted expression of wt-vGN-mFc or yydd-     
vGN-mFc, 2 mL of media from CDH-wt-vGN-mFc or 
CDH-yydd-vGN-mFc transfected 293T cells seeded in 6-      
well-plates was used in affinity chromatography, while 20 L 
eluate of each sample was obtained and used for immunob-
lotting. 
1.3  Immunoblotting 
Immunoblot assays were performed as previously described 
[21]. Immunoblot detection of the wt-vGN-mFc and 
yydd-vGN-mFc was performed either with anti-Penta.His 
antibody (1:2500; Sigma) or with secondary antibody (goat 
anti-mouse IgG peroxidase conjugate) alone.  
1.4  Labeling of wt-vGN and yydd-vGN 
293T cells were transfected with pSecTag2A-wt-vGN-mFc 
or pSecTag2A-yydd-vGN-mFc. Cells were passeged at 10 h 
post-transfection. Approximately 36 h after transfection, the 
cells were radiolabeled with [35S]-methionine/cysteine or 
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[35S]-sulfate for 10 h. Labeled cells were lysed and used in 
affinity chromatography. The eluate was used for autoradi-
ography as previously described [22].  
1.5  Tumor formation assays in nude mice 
All animal experiments were carried out according to the 
institutional ethical guidelines for animal experiments at the 
Guangzhou Institute of Medicine and Health, Chinese 
Academy of Sciences. NIH3T3 cells stably expressing the 
empty vector (CDH-CMV-EF-Puro) and NIH3T3 cells sta-
bly expressing vGPCR, hGRO-, wt-vGN-mFc or yydd-       
vGN-mFc were injected subcutaneously into the flanks of 3- 
to 5-week-old mice (athymic, nude/nude). Nude mice were 
sacrificed four weeks after inoculation, and the tumor 
weights were determined as described before [22]. 
Total RNA was isolated from the tumors and cDNA was 
prepared using the kit according to the manufacturer’s in-
structions (Invitrogen, Shanghai, China). The expression of 
hGRO-, vGPCR, wt-vGN-mFc and yydd-vGN-mFc 
mRNA in the tumors was detected by RT-PCR, as previ-
ously reported [21,22].  
2  Results 
2.1  wt-vGN but not yydd-vGN is modified by sulfation 
pSecTag2A-wt-vGN-mFc and pSecTag2A-yydd-vGN-mFc 
contained the vGN-mFc chimera, in which the Ig leader 
sequence was upstream of the DNA fragment (vGN) en-
coding 1–49 amino acids of vGPCR or yydd-vGPCR, and 
the mFc fragment with 6×His.tag tail was fused to the 3′ end 
of vGN (Figure 1). The vGN-mFc chimeras of CDH-wt-      
vGN-mFc or CDH-yydd-vGN-mFc were identical to their 
pSecTag2A counterparts apart from the restriction sites.   
293T cells were transfected with pSecTag-wt-vGN-mFc 
or pSecTag-yydd-vGN-mFc. wt-vGN-mFc and yydd-vGN-     
mFc were purified and used for CBB staining or immunob-
lotting. One exclusive band of approximately 40–45 kD was 
identifid by CBB staining for each sample, matching the 
predicted size of wt-vGN-mFc or yydd-vGN-mFc (Figure 
2). The wt-vGN-mFc band was of a weaker intensity than 
that of yydd-vGN-mFc, implying lower expression levels. 
Immunoblotting with anti-Penta His antibody verified that 
the purified proteins were wt-vGN-mFc and yydd-vGN-     
mFc. Immunoblotting without primary antibody demon-
strated that both wt-vGN-mFc and yydd-vGN-mFc were 
secreted into the media. Additionally, the band for 
yydd-vGN-mFc was wider than that of wt-vGN-mFc, which 
correlated with the CCB staining result (Figure 2).  
The results of [35S]-methionine/cysteine labeling demon-
strated that both the lanes for wt-vGN-mFc and yydd-      
vGN-mFc had bands of 40–45 kD, confirming the CBB 
staining results. In the [35S]-sulfate labeling assay, a band of 
4045 kD was found exclusively in the wt-vGN-mFc lane, 
clearly demonstrating that only wt-vGN-mFc incorporated 
[35S]-sulfate (Figure 2). All the data elucidated that both 
wt-vGN-mFc and yydd-vGN-mFc were secreted, and 
wt-vGN but not yydd-vGN possessed tyrosine sulfation  
 
 
Figure 1  Diagram of wt-vGN-mFc and yydd-vGN-mFc. Pcmv, cmv promoter; Ig leader, Ig-chain leader sequence; vGN, wt-vGPCR or yydd-vGPCR 
extracellular N-terminus (1–49 amino acids); mFc, mouse Fc hinge; 6×His, 6×His tag. 
 
Figure 2  wt-vGN but not yydd-vGN efficiently incorporates radiolabeled sulfate. wt-vGN-mFc and yydd-vGN-mFc were purified from both cell lysates 
and media supernatant. The purified peptides were isolated by 10% SDS-PAGE and used for experiments as described in Materials and methods. A, 
[35S]-methionine/cysteine (Met/Cys) labeling (upper); [35S]-sulfate (SO4) labeling (middle); coomassie brilliant blue staining (bottom). B, 5% input for Pen-
ta-his IB (upper); 5% input for actin immunoblotting (middle); eluate from media supernatant for immunoblotting, in which only the goat anti-mouse IgG 
peroxidase secondary conjugate was used (bottom). CBB staining: coomassie brilliant blue staining. Wt, wt-vGN-mFc; yydd, yydd-vGN-mFc; wcl, whole 
cell lysate; media, media supernatant. 
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modifications. 
2.2  Unsulfated vGN reduces the tumorigenicity of 
hGRO- in nude mice  
In our previous study, the average tumor weight of the nude 
mice injected with NIH3T3/hGRO- cells mixed with 
NIH3T3/yydd-vGPCR cells was only 38% of that of nude 
mice injected with NIH3T3/hGRO- cells alone [21]. This 
suggested that yydd-vGPCR (precisely its unsulfated extra-
cellular N-terminus) could affect the tumorigenicity of 
hGRO-. To investigate if the unsulfated N-terminus of 
yydd-vGPCR reduces the tumorigenicity of hGRO-, nude 
mice were subcutaneously injected with NIH3T3 cells sta-
bly expressing hGRO-, wt-vGN-mFc, or yydd-vGN-mFc 
(Table 1). The average tumor weight of the hGRO- group 
was 1571.625 mg, 1994.875 mg for the hGRO-/wt-vGN 
group and 602.4 mg for the hGRO-/yydd-vGN group 
(Figure 3A), demonstrating that the tumorigenicity of 
hGRO- was greatly reduced by yydd-vGN but not wt-vGN. 
RT-PCR showed that hGRO-, wt-vGN and yydd-vGN 
were well expressed in the nude mouse tumors (Figure 3B). 
The average tumor weight of hGRO-/yydd-vGN group 
was only 38% of that of the hGRO- group and the tumor 
weight of the hGRO-/wt-vGN group was 125% of that of 
the hGRO- group. These data correlated with our previous 
data, in which the average tumor weight of the hGRO-/      
yydd-vGPCR group was only 38% of that of the hGRO- 
group [21].  
Table 1  NIH3T3 cells to test the effect of vGN on the tumorigenicity of 
hGRO-α in vivoa) 
Cell number (×106) 
Mouse group Puro hGRO- wt-vGN yydd-vGN 
Control 6 0 0 0 
hGRO- 5 1 0 0 
hGRO-/wt-vGN 3 1 2 0 
hGRO-/yydd-vGN 3 1 0 2 
a) Puro, NIH3T3 stably expressing CDH-CMV-EF-Puro empty vector; 
hGRO-, NIH3T3 expressing hGRO-; wt-vGN, NIH3T3 expressing 
wt-vGN-mFc; yydd-vGN, NIH3T3 expressing wt-vGN-mFc. 
2.3  Unsulfated vGN reduces the tumorigenicity of 
vGPCR in nude mice 
Our previous study demonstrated that hGRO- binds 
vGPCR in a sulfotyrosine-dependent manner, and suggested 
that hGRO- promotes vGPCR tumorigenicity through auto-
crine signaling. To further test if the unsulfated N-terminus of 
yydd-vGPCR affects hGRO- autocrine signaling in 
vGPCR tumorigenicity, nude mice were subcutaneously 
injected with NIH3T3 cells stably expressing vGPCR, 
wt-vGN-mFc, or yydd-vGN-mFc (Table 2). The average 
tumor weight of the vGPCR group was 659.5 mg, 685 mg 
for the vGPCR/wt-vGN group and 417.5 mg for the 
vGPCR/yydd-vGN group (Figure 4A). RT-PCR confirmed 
good expression of vGPCR, wt-vGN and yydd-vGN in the 
nude mouse tumors (Figure 4B). The average tumor weight 
of the vGPCR/yydd-vGN group was 60% of that of the 
vGPCR group and the average tumor weight of the 
vGPCR/wt-vGN group was almost identical (105%) to that 
of the vGPCR group. These data support the conclusion that 
unsulfated yydd-vGN inhibits vGPCR tumorigenicity in 
nude mice. 
3  Discussion 
vGPCR is a bona fide signaling molecule that is implicated 
in KSHV-associated malignancies. This seven membrane-        
spanning protein is constitutively activated; however, ligand 
association upregulates (GRO-) or downregulates (IP-10) 
its signaling. Our previous study revealed that tyrosine sul-
fation on Y26 and Y28 of the N-terminus of vGPCR is cru-
cial for GRO-α but not IP-10 association. An unsulfated 
YYDD mutant (yydd-vGPCR) demonstrated similar signal-
ing as that of wild-type vGPCR, however, the tumorigenicity 
of yydd-vGPCR in nude mice completely disappeared. A 
mode of action was proposed based on our previous study, 
whereby hGRO- promotes signaling and tumorigenicity in 
a sulfotyrosine-dependent manner [21]. Interestingly, in 
nude mice experiments, when NIH3T3 cells expressing 
yydd-vGPCR were mixed with hGRO- expressing 
NIH3T3 cells, the tumorigenicity of hGRO- was reduced  
 
 
Figure 3  Unsulfated yydd-vGN affects the tumor formation triggered by hGRO- in vivo. A, NIH3T3 cells stably expressing hGRO-, wt-vGN-mFc or 
yydd-vGN-mFc were inoculated into the flanks of 3- to 5-week-old nude mice. Nude mice were sacrificed four weeks after inoculation and the tumor weight 
was determined. Data represent mean values and error bars denote standard deviations (average tumor weight±SD), with P-values relative to hGRO- group 
as calculated by Student’s t-tests. B, The expression of hGRO-, wt-vGN-mFc and yydd-vGN-mFc in the tumors was detected by RT-PCR. 
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Table 2  NIH3T3 cells to test the effect of vGN on the tumorigenicity of 
vGPCR in vivoa) 
Cell number (×106) 
Mouse group Puro vGPCR wt-vGN yydd-vGN 
Control 2.5 0 0 0 
vGPCR 2.4 0.1 0 0 
wt-vGN/vGPCR 1.9 0.1 0.5 0 
yydd-vGN/vGPCR 1.9 0.1 0 0.5 
a) Puro, NIH3T3 stably expressing CDH-CMV-EF-Puro empty vector; 
vGPCR, NIH3T3 expressing vGPCR; wt-vGN, NIH3T3 expressing 
wt-vGN-mFc; yydd-vGN, NIH3T3 expressing wt-vGN-mFc. 
 
 
by 60% compared with the hGRO- only group. Thus, we 
hypothesized that these important residues of the extracel-
lular N-terminus of vGPCR might facilitate hGRO- to 
associate with its other cell surface-expressing receptors 
(named GR here) and regulate their signaling. hGRO- 
could not associate with yydd-vGPCR and the unsulfated 
N-terminus of this molecule might block hGRO- associa-
tion with GR through some unknown mechanism. This 
could explain why the average tumor weight of nude mice 
injected with NIH3T3 cells expressing yydd-vGPCR mixed 
with NIH3T3 cells expressing hGRO- was much reduced 
compared with those injected with NIH3T3 hGRO- cells 
alone.  
yydd-vGN-mFc and wt-vGN-mFc were expressed and 
purified in this study to investigate if the unsulfated extra-
cellular N-terminus of vGPCR negatively regulates the tu-
morigenicity of hGRO-. mFc was introduced to facilitate 
the expression and characterization of the secreted peptides. 
The [35S]-sulfate labeling assay verified that wt-vGN-mFc 
but not yydd-vGN-mFc has the tyrosine sulfation modifica-
tion, which implies these two peptides are suitable for in 
vivo studies mimicking the N-terminus of wt-vGPCR and 
yydd-vGPCR accordingly. 
Injection of nude mice with NIH3T3 cells expressing 
hGRO- mixed with NIH3T3/yydd-vGN-mFc cells resulted 
in far smaller tumors than injection with NIH3T3/hGRO- 
cells. Furthermore, the average tumor weight of the 
hGRO-/wt-vGN group was higher (125%) than that of the 
hGRO- only group. This correlated with our previous data. 
This may be because wt-vGN-mFc enhances the association 
of hGRO- with GR. However, it cannot function as a re-
ceptor and promote tumor formation through an autocrine 
pathway as vGPCR does, which may explain why the aver-
age tumor weight of the hGRO-/vGPCR group is almost 
two fold that of the hGRO- group plus the vGPCR group 
in our previous study.  
hGRO- promotes vGPCR tumorigenicity through auto-
crine signaling and yydd-vGN could attenuate the tumor-
igenicity of hGRO-, implying that the tumorigenicity of 
vGPCR expressing NIH3T3 cells could be affected by 
blocking hGRO- association with its cellular receptor. 
Nude mice data verified this possibility, in which the aver-
age tumor weight of vGPCR/yydd-vGN group was 60% of 
that of the vGPCR group, and the average tumor weight of 
the vGPCR/wt-vGN group was almost identical (104%) to 
that of vGPCR group (Figure 4).  
Based on the data generated in this study and our previ-
ous study, we present a model in which the tumorigenicity 
of hGRO- is diminished by the unsulfated extracellular 
N-terminal region of vGPCR (Figure 5). In this model, the 
extracellular N-terminus of vGPCR associates with hGRO- 
to promote hGRO- association with its cellular receptor. Its 
unsulfated counterpart, the N-terminus of yydd-vGPCR, 
cannot bind hGRO- and can block hGRO- association 
with its cellular receptor. We hypothesize that vGPCR has 
two docking sites in its intracellular N-terminus, which can 
associate with hGRO- and the cell surface hGRO- re-
ceptor (GR) separately. The sulfation modification at the 
N-terminus of vGPCR works like a “swivel clamp” in the 
scaffold to “fasten” hGRO- to GR, enabling binding be-
tween hGRO- and GR. In contrast, the N-terminus of yydd- 
vGPCR could not bind hGRO- because of the loss of the 
sulfotyrosines. However, it could still occupy the docking 
site in GR and inhibit hGRO- association with GR, ex-
plaining why yydd-vGPCR could reduce the tumorigenicity 
of hGRO- in vivo. Secreted yydd-vGN, which has the 
same sequence and a similar structure to the unsulfated 
N-terminus of yydd-vGPCR, could reduce the tumorigenicity  
 
 
Figure 4  Unsulfated yydd-vGN affectes the tumor formation triggered by vGPCR in vivo. A, NIH 3T3 cells stably expressing vGPCR, wt-vGN-mFc or 
yydd-vGN-mFc were inoculated into the flanks of 3- to 5-week-old nude mice. Nude mice were sacrificed four weeks after inoculation, and the tumor weight 
was determined. Data represent mean values and error bars denote standard deviations (average tumor weight±SD), with P-values relative to vGPCR group 
as calculated by Student’s t-tests. B, The expression of vGPCR,wt-vGN-mFc and yydd-vGN-mFc in the tumors was detected by RT-PCR. 
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Figure 5  A hypothetical model of the extracellular N-terminus of vGPCR function in hGRO- signaling. vGPCR acts as both a receptor and a ligand on 
the cellular surface. Left panel, hGRO-α binds to vGPCR in a sulfotyrosine-dependent manner, and the sulfate modified extracellular N-termini of vGPCR 
enables hGRO- association with its cellular receptor (GR). The sulfation-free vGPCR mutant (yydd-vGPCR) cannot associate with hGRO-, and its unsul-
fated extracellular N-terminus blocks hGRO- association with GR. Right panel, wt-vGN and yydd-vGN have the same amino acid sequence and similar 
structure to the extracellular N-terminus of vGPCR or yydd-vGPCR accordingly. Sulfated wt-vGN promotes hGRO- association with GR. However, un-
sulfated yydd-vGN blocks hGRO- association with GR and negatively regulates downstream signaling. 
of hGRO- and reduce the tumorigenicity of vGPCR in 
nude mice by blocking the hGRO- association with its 
cellular receptor (GR). This provides a good opportunity for 
the development of therapeutic agents targeting hGRO- 
that could be applied to the treatment of cancers caused by 
KSHV vGPCR or abnormal hGRO- expression. 
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